Oxford, U.K. 19 July 2021: Sensyne Health plc (LSE: SENS) ( Sensyne or the Company ), the ethical AI company, announces an update on its strategy which now includes exploring a potential dual-listing on Nasdaq amongst other options. As stated in our financial year end trading update on 27 May 2021, the Company continues to explore strategic opportunities, including making acquisitions, that leverage its organic growth and create additional shareholder value. Any decision to list in the US would complement the Company s primary listing on the AIM market of the London Stock Exchange and Sensyne remains committed to being a UK-headquartered company. Any acquisition or strategic equity partnership would
Sensyne Health PLC (AIM:SENS) | RNS | Sensyne Health PLC - Sensyne Health Provides Strategic Update
proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
Investegate |Sensyne Health PLC Announcements | Sensyne Health PLC: NED Appointment
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Oxford, U.K. 5 February 2021 : Sensyne Health plc (LSE: SENS) ( Sensyne or the Company or the Group ), the UK Clinical AI company, announces that it has appointed Hina Zaman as Managing Director of its Healthcare Division and Martin Gouldstone as Chief Business Officer of its Life Sciences Division. Hina Zaman joins Sensyne from Babylon Health, where as Product Director she led the company s global product for value-based care and previously its global product proposition in the women s health space. Prior to that, Hina founded the UK s first virtual care platform for women s health, pioneering a new model of personalised, proactive care for health consumers. Hina has extensive experience as a healthcare management consultant, leading change initiatives across the NHS commissioning and provider landscape while at Finnamore Ltd. (now part of GE Healthcare), and in US healthcare systems while at Deloitte